PHAT

Phathom Pharmaceuticals Inc.

Price

$9.32

return (12m)

-10.21%

p/e

-7.89

p/bv

-2.27

DIVIDEND YIELD

0.00%

PHAT price

Phathom Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PHAT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-13.94%

3 months

-19.52%

1 year

-10.21%

2 years

-27.70%

5 years

-70.46%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PHAT

Valuation

P/E

-7.89

Sector -4.38

Industry -4.38

P/BV

-2.27

Sector 2.02

Industry 2.02

P/Revenue (PSR)

3.26

Sector -4.40

Industry -4.40

EV/EBITDA

-322.07

Sector -263.09

Industry -263.09

EV/EBIT

-307.79

Sector -702.90

Industry -702.90

P/EBITDA

-22.23

Sector -4.39

Industry -4.39

P/EBIT

-21.91

Sector -4.73

Industry -4.73

P/Total Assets

2.39

Sector 1.49

Industry 1.49

P/Net Current Assets

-2.08

Sector -11.70

Industry -11.70

P/Working Capital

5.50

Sector -3.19

Industry -3.19

EPS

-1.18

Sector -2.14

Industry -2.14

BVPS

-4.10

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

82.93%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-3.19%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-3.34%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-16.96%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-41.34%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.23

Sector 0.03

Industry 0.03

Profitability

ROE

28.78%

Sector -65.14%

Industry -65.14%

ROA

-30.29%

Sector -65.53%

Industry -65.53%

ROIC

-20.62%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1.92

Sector 2.90

Industry 2.90

Net Debt / EBITDA

7.55

Sector -6.07

Industry -6.07

Net Debt / EBIT

7.21

Sector -8.26

Industry -8.26

Net Debt / Equity

0.05

Sector -1.07

Industry -1.07

Gross Debt / Equity

-0.48

Sector -0.05

Industry -0.05

Equity/Assets

-1.05

Sector 0.41

Industry 0.41

Liabilities/Assets

2.05

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-7.19%

Sector -

Industry -

Fundamentals PHAT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PHAT Phathom Pharmaceuticals Inc.	$9.32	-7.72%	0.00%	-7.89	-2.27	28.78%	-41.34%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PHAT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

United States

8 years

Founded: 2018

2019

Time since IPO - 7 years

55

Employees

Phathom Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $781.20 million, with shareholders equity totaling $-344.27 million.

The company employs approximately 55 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Phathom Pharmaceuticals Inc. reported $239.65 million in revenue, generating net income of $-99.07 million.

Key financial metrics include a P/E ratio of -7.89, a price-to-book (P/B) ratio of -2.27, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PHAT.

Market cap

$781.20 million

Net worth

$-344.27 million

$-344,270,000.00

Assets

$327.07 million

$327,070,000.00

Total Shares Outstanding

84.00 million

84,000,000

Average Daily Trading Volume

$1.33 million

$1,331,888.00

Sector

Health Care

Industry

Biotechnology

PHAT

PHAT revenue and profits

Financial Results PHAT

DRAG THE FRAME TO SEE MORE DATA

PHAT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Phathom Pharmaceuticals (PHAT) today?

A cotação de Phathom Pharmaceuticals (PHAT) hoje está em US$ 9.32, com uma variação de -10.21% em relação ao último ano. A cotação de Phathom Pharmaceuticals (PHAT) iniciou o ano negociando na casa dos US$ 16.59 e hoje está em US$ 9.32. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Phathom Pharmaceuticals (PHAT) e dados de ações do Ibovespa e mercados internacionais.

Quando Phathom Pharmaceuticals (PHAT) paga dividendos?

Phathom Pharmaceuticals (PHAT) não distribuiu dividendos no último ano.

Is Phathom Pharmaceuticals (PHAT) a good investment?

Atualmente, Phathom Pharmaceuticals (PHAT) está cotada a US$ 9.32, com um P/L de -7.89, representando um desvio de -414% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -10.21 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -10.21%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Phathom Pharmaceuticals (PHAT) stock?

Investir em ações de Phathom Pharmaceuticals (PHAT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Phathom Pharmaceuticals (PHAT) yield today?

A rentabilidade de Phathom Pharmaceuticals (PHAT) foi de -13.94% no último mês, -10.21% no último ano e -70.46% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Phathom Pharmaceuticals (PHAT) hoje, o investimento total seria de US$ 932.00, com base na cotação atual de US$ 9.32.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 836.84
Em 5 anos: US$ 275.31
Em 10 anos: US$ 932.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PHAT

Phathom Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PHAT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PHAT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc.

United States

8 years

2019

55

PROFIT X PRICE PHAT

Financial Results PHAT

PHAT cash flow

Asset, Revenue and Profit Growth - PHAT

PHAT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions